Drugs / Etentamig
Etentamig
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06896916 | Aug 2025 → Mar 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06223516 | Jun 2024 → Feb 2027 expected | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05650632 | Mar 2023 → Aug 2029 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT05259839 | Oct 2022 → Sep 2033 expected | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05286229 | Mar 2022 → Mar 2026 overdue | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07600151 | Dec 2026 → Sep 2036 expected | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07420959 | Oct 2026 → Oct 2036 expected | Waldenstrom macroglobulinemia | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06158854 | Apr 2024 → Feb 2028 expected | AL amyloidosis | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03933735 | Jun 2019 → May 2026 overdue | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07095452 | Jan 2026 → Jan 2042 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06158841 | May 2024 → Dec 2027 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04453397 | — | plasma cell myeloma | TeneoOne Inc. | No longer available | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-05 | AbbVie | AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 abbvie.com ↗ |
| 2021-06-24 | AbbVie | AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma abbvie.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etentamig | “ABBV-383 (Etentamig)” NCT06158854 ↗ |
| Known as | ABBV-383 | “Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM).” NCT05650632 ↗4“Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM.” NCT06223516 ↗ “Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM.” NCT05286229 ↗ “Etentamig (ABBV-383) as an Intravenous (IV) Infusion” NCT06892522 ↗ |
| Known as | Anti-bcma x acd3 t-bsab tnb-383b | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314973 ↗ |
| Known as | TNB-383B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03933735 ↗ |
| Modality | Monoclonal antibody | “bispecific antibody” NCT04453397 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT05259839 ↗ |